ArticleRespiratory research2007
Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate.
Article in Respiratory research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies.Clinical drug investigation · 2009Pooled it
- Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk.International journal of chronic obstructive pulmonary disease · 2016Trial
- Efficacy and safety of fluticasone furoate 100 μg and 200 μg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study.BMC pulmonary medicine · 2014Trial
- Differential association of fluticasone furoate and budesonide with clinically detected COVID-19: a retrospective cohort study.BMJ open respiratory research · 2026Article
- Article
- MicroED Structures of Fluticasone Furoate and Fluticasone Propionate Provide New Insights into Their Function.Crystal growth & design · 2025Article
- MicroED Structures of Fluticasone Furoate and Fluticasone Propionate Provide New Insights to Their Function.bioRxiv : the preprint server for biology · 2024Article
- Review
- Effects of inhaled corticosteroids (ICS) on lung microbiota and local immune response in long-term treatment of chronic obstructive pulmonary disease (COPD): utility of titration and therapeutic index.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- The subtle nuances of intranasal corticosteroids.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale · 2021Article
- Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index.Journal of asthma and allergy · 2021Review
- The Global Initiative for Asthma 2019 recommendation for mild asthma - A critique.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2020Article
- Review
- Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma.Respiratory research · 2016Article
- Inhaled corticosteroids: potency, dose equivalence and therapeutic index.British journal of clinical pharmacology · 2015Review
- Review
- Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.Drugs · 2014Review
- Structures and mechanism for the design of highly potent glucocorticoids.Cell research · 2014Article
- Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.International journal of chronic obstructive pulmonary disease · 2014Review
- Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluticasone furoate (FF)--USAN approved name, a new topically active glucocorticoid has been recently identified. The aim of this study was to characterise the binding affinity of this compound to the human lung glucocorticoid receptor in relation to other glucocorticoids. Additionally, we sought to determine the binding behaviour of fluticasone furoate to human lung tissue. The glucocorticoid receptor binding kinetics of fluticasone furoate revealed a remarkably fast association and a slow dissociation resulting in a relative receptor affinity (RRA) of 2989 +/- 135 with reference to dexamethasone (RRA: 100 +/- 5). Thus, the RRA of FF exceeds the RRAs of all currently clinically used corticosteroids such as mometasone furoate (MF; RRA 2244), fluticasone propionate (FP; RRA 1775), ciclesonide's active metabolite (RRA 1212 - rat receptor data) or budesonide (RRA 855). FP and FF displayed pronounced retention in human lung tissue in vitro. Lowest tissue binding was found for MF. There was no indication of instability or chemical modification of FF in human lung tissue. These advantageous binding attributes may contribute to a highly efficacious profile for FF as a topical treatment for inflammatory disorders of the respiratory tract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.